Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Equivalents: 2015-2025

Historic Cash & Equivalents for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to $143.4 million.

  • Cartesian Therapeutics' Cash & Equivalents fell 34.59% to $143.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.4 million, marking a year-over-year decrease of 34.59%. This contributed to the annual value of $212.6 million for FY2024, which is 176.44% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Cash & Equivalents of $143.4 million as of Q3 2025, which was down 10.57% from $160.3 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Cash & Equivalents registered a high of $219.2 million during Q3 2024, and its lowest value of $76.9 million during Q4 2023.
  • Over the past 3 years, Cartesian Therapeutics' median Cash & Equivalents value was $125.9 million (recorded in 2023), while the average stood at $136.5 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 176.44% in 2024, then crashed by 34.59% in 2025.
  • Cartesian Therapeutics' Cash & Equivalents (Quarterly) stood at $114.1 million in 2021, then declined by 6.68% to $106.4 million in 2022, then declined by 27.74% to $76.9 million in 2023, then soared by 176.44% to $212.6 million in 2024, then tumbled by 34.59% to $143.4 million in 2025.
  • Its Cash & Equivalents stands at $143.4 million for Q3 2025, versus $160.3 million for Q2 2025 and $180.4 million for Q1 2025.